Every 10-Q that DarioHealth Corp. (DRIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DRIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DRIO filings page.
DarioHealth Corp. reported for the quarter and six months ended June 30, 2026 that it remains a single-segment digital therapeutics and whole‑person health platform focused on chronic and behavioral conditions. Total assets were $96.6 million, including $6.6 million in cash and cash equivalents and $7.3 million in short‑term deposits, against a long‑term loan of $31.1 million and an Orbimed warrant liability of $15 thousand.
Revenues were $5.2 million and $10.8 million for the three and six months, down 3.6% and 11.2% year over year, mainly from lower pharma‑channel revenue, partly offset by growth in channel partners and direct‑to‑consumer sales. Gross margin improved, supported by lower amortization, lower hosting costs and a $369 thousand IEEPA tariff refund benefit. Operating expenses fell sharply: research and development, sales and marketing, and general and administrative all declined, reflecting post‑merger efficiencies and reduced stock‑based compensation.
The company’s net loss narrowed to $7.9 million for the quarter and $16.2 million year‑to‑date, from $13.0 million and $22.2 million, respectively, aided by lower operating and financial expenses. Operating cash outflow was $12.1 million for the six months. Management notes an accumulated deficit of $468.3 million but cites a July 22, 2026 registered direct offering providing approximately $23.5 million in gross proceeds and believes available funds support operations for at least twelve months from issuance of these statements.
DarioHealth Corp. reported a first-quarter 2026 net loss of $8.2M, narrowing from $9.2M a year earlier, as operating expenses declined. Revenue fell 17.3% to $5.6M, mainly due to non-recurring pharma revenue in 2025, partly offset by stronger channel partner and direct-to-consumer sales.
Gross margin stayed broadly stable at about 57%, but the company used $6.0M of cash in operations and ended the quarter with $15.0M in cash and $5.0M in short-term deposits. Management disclosed “substantial doubt” about its ability to continue as a going concern over the next 12 months without additional capital or improved performance.
DarioHealth Corp. reported Q3 2025 results. Revenue was $5,007k, down from $7,423k a year ago, as services declined while consumer hardware was roughly flat. Gross profit was $3,015k. Operating loss was $9,484k and net loss was $10,466k.
For the first nine months of 2025, revenue was $17,128k versus $19,436k in 2024, with a net loss of $32,683k. Cash and cash equivalents were $31,907k as of September 30, 2025. Long‑term loan balance was $30,617k and warrant liability was $2,244k. Shares outstanding were 6,768,184 on November 11, 2025.
On April 30, 2025, the company refinanced with a $32,500 Callodine loan at SOFR plus 7.75%, with up to $17,500 of additional draws. After not meeting a financial covenant on August 15, 2025, DarioHealth and lenders executed a November 5, 2025 amendment that reset covenants, waived testing for Q2–Q3 2025, added a $10,000 minimum consolidated unencumbered liquid assets covenant, and repriced lender warrants to a $15.35 exercise price; a $2,500 conversion right was also set at $15.35 per share.
DarioHealth Corp. reported total revenues of $5.369 million for the quarter ended June 30, 2025, split between Services $3.661M and Consumer hardware $1.708M. Gross profit was $2.964M for the quarter and $6.846M for the six months, while operating expenses were $12.164M for the quarter, producing an operating loss of $9.200M. The company recorded a net loss of $12.990M for the quarter and $22.217M for the six months; basic and diluted loss per share was $0.18 for the quarter and $0.33 for six months.
On the balance sheet, cash and cash equivalents were $21.954M (down from $27.764M at year-end), total assets were $108.325M, and accumulated deficit totaled $422.971M. The company refinanced with a $32.5M Callodine credit agreement on April 30, 2025, but did not meet one covenant as of June 30, 2025; Callodine waived the default conditional on a successful equity cure by November 15, 2025. Management discloses that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from issuance.